Willamette Valley Cancer Institute and Research Ctr.

Emergency Messages as of 5:16 PM, Tue. Aug 11

No information currently posted.

logo

Subscribe to receive FlashAlert messages from Willamette Valley Cancer Institute and Research Ctr..

Manage my existing Subscription

News Release

Willamette Valley Cancer Institute And Research Center Expands Access To Advanced PET/CT Technology To Strengthen Comprehensive Cancer Care Offering (Photo) - 08/11/26

FOR IMMEDIATE RELEASE

WVCI Expands Access to Advanced PET/CT Technology to Strengthen Comprehensive Cancer Care Offering

Powerful new PET/CT technology advances WVCI’s commitment to state-of-the-art imaging, coordinated cancer care, and the future introduction of radiopharmaceutical capabilities. 
 

EUGENE, Ore. — [August, 11, 2026] — Willamette Valley Cancer Institute and Research Center (“WVCI”) announces the addition of PET/CT imaging technology with the installation of a new Siemens Biograph Trinion PET/CT scanner at its Eugene location this month. The technology provides patients a new, convenient option for advanced imaging and supports a higher level of coordinated cancer care for patients in the Willamette Valley.
 

PET/CT imaging combines PET (positron emission tomography), which shows tumor activity and location, with CT (computed tomography), which shows detailed images of the body’s anatomy, in one advanced scan. Together, these technologies help physicians identify health concerns quickly and accurately, supporting early detection, accurate diagnosis, and confident treatment planning.

By using PET/CT imaging early in the care planning process, WVCI care teams can see where cancer may be present and whether it has spread. This information helps physicians determine the stage of cancer, plan the next steps in care, and monitor how well treatment is working over time.
 

“Our new scanner gives our physicians highly detailed images that can detect exceptionally small areas of concern,” said Tina Nelson, Senior PET/CT technologist at WVCI.
 

The new PET/CT system is also designed with the patient experience in mind. Faster, lower-dose imaging may help shorten the time patients spend in the scanner and limit radiation exposure. Comfort features, including mood lighting and continued communication with imaging staff, are intended to help patients feel informed, supported, and more at ease during the exam.
 

“We want the experience to feel as reassuring as possible,” explains Nelson. “The new features help our imaging team do that by staying connected with patients and fostering a calming environment, which helps minimize clinical anxiety.”  
                                                                             

The PET/CT technology also supports WVCI’s introduction of radiopharmaceutical capabilities later this year. Radiopharmaceuticals are specialized medicines that contain small amounts of radioactive material and may be used to help diagnose and, in some cases, treat certain cancers. As this program develops, WVCI will share additional information with patients, referring providers, and community partners.


“For patients, this is about more than new technology,” Nelson said. “It brings cutting-edge imaging to where our patients are, alongside the cancer care team they already know. It’s helping reduce the physical and emotional burden of traveling to multiple locations for separate appointments.”
 

The new PET/CT scanner is available now for patients of WVCI. Details about future radiopharmaceutical capabilities will be shared as they are finalized later this year.

Patients who would like more information about WVCI’s imaging and cancer care services may call 541.683.5001. 
 

About Willamette Valley Cancer Institute and Research Center

The Willamette Valley Cancer Institute and Research Center is a member of the US Oncology Network of over 1,200 independent physicians, dedicated to delivering value-based, integrated care to patients – close to home in Albany, Corvallis, Eugene, Florence, Newport, and Springfield.  As part of the Network community, we share expertise and resources to advance local cancer care and deliver better patient outcomes. WVCI also participates in clinical trials through US Oncology Research and Sarah Cannon Research Institute, which have played a role in more than 100 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date.

 

Media Contact:
  Christy Curtis
  Willamette Valley Cancer Institute and Research Center
  541-632-3156
  Christy.Curtis@usoncology.com

 

Attached Media Files: WVCI_Adds_PETCT_Technology_Aug2026.pdf,

Willamette Valley Cancer Institute And Research Center Expands Access To Advanced PET/CT Technology To Strengthen Comprehensive Cancer Care Offering (Photo) - 08/11/26

FOR IMMEDIATE RELEASE

WVCI Expands Access to Advanced PET/CT Technology to Strengthen Comprehensive Cancer Care Offering

Powerful new PET/CT technology advances WVCI’s commitment to state-of-the-art imaging, coordinated cancer care, and the future introduction of radiopharmaceutical capabilities. 
 

EUGENE, Ore. — [August, 11, 2026] — Willamette Valley Cancer Institute and Research Center (“WVCI”) announces the addition of PET/CT imaging technology with the installation of a new Siemens Biograph Trinion PET/CT scanner at its Eugene location this month. The technology provides patients a new, convenient option for advanced imaging and supports a higher level of coordinated cancer care for patients in the Willamette Valley.
 

PET/CT imaging combines PET (positron emission tomography), which shows tumor activity and location, with CT (computed tomography), which shows detailed images of the body’s anatomy, in one advanced scan. Together, these technologies help physicians identify health concerns quickly and accurately, supporting early detection, accurate diagnosis, and confident treatment planning.

By using PET/CT imaging early in the care planning process, WVCI care teams can see where cancer may be present and whether it has spread. This information helps physicians determine the stage of cancer, plan the next steps in care, and monitor how well treatment is working over time.
 

“Our new scanner gives our physicians highly detailed images that can detect exceptionally small areas of concern,” said Tina Nelson, Senior PET/CT technologist at WVCI.
 

The new PET/CT system is also designed with the patient experience in mind. Faster, lower-dose imaging may help shorten the time patients spend in the scanner and limit radiation exposure. Comfort features, including mood lighting and continued communication with imaging staff, are intended to help patients feel informed, supported, and more at ease during the exam.
 

“We want the experience to feel as reassuring as possible,” explains Nelson. “The new features help our imaging team do that by staying connected with patients and fostering a calming environment, which helps minimize clinical anxiety.”  
                                                                             

The PET/CT technology also supports WVCI’s introduction of radiopharmaceutical capabilities later this year. Radiopharmaceuticals are specialized medicines that contain small amounts of radioactive material and may be used to help diagnose and, in some cases, treat certain cancers. As this program develops, WVCI will share additional information with patients, referring providers, and community partners.


“For patients, this is about more than new technology,” Nelson said. “It brings cutting-edge imaging to where our patients are, alongside the cancer care team they already know. It’s helping reduce the physical and emotional burden of traveling to multiple locations for separate appointments.”
 

The new PET/CT scanner is available now for patients of WVCI. Details about future radiopharmaceutical capabilities will be shared as they are finalized later this year.

Patients who would like more information about WVCI’s imaging and cancer care services may call 541.683.5001. 
 

About Willamette Valley Cancer Institute and Research Center

The Willamette Valley Cancer Institute and Research Center is a member of the US Oncology Network of over 1,200 independent physicians, dedicated to delivering value-based, integrated care to patients – close to home in Albany, Corvallis, Eugene, Florence, Newport, and Springfield.  As part of the Network community, we share expertise and resources to advance local cancer care and deliver better patient outcomes. WVCI also participates in clinical trials through US Oncology Research and Sarah Cannon Research Institute, which have played a role in more than 100 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date.

 

Media Contact:
  Christy Curtis
  Willamette Valley Cancer Institute and Research Center
  541-632-3156
  Christy.Curtis@usoncology.com

 

Attached Media Files: WVCI_Adds_PETCT_Technology_Aug2026.pdf,